Eteplirsen: $300,000 per patient per year

Controversy Continues Over Muscular Dystrophy Drug, Despite FDA Approval
September 24, 2016
http://www.npr.org/sections/health-shots/2016/09/24/495174472/controversy-continues-over-muscular-dystrophy-drug-despite-fda-approval

Just 12 boys had been involved in the key study, and just about everybody agreed that the research was deeply flawed

In the meantime, Sarepta can start charging $300,000 per patient per year for treatment with eteplirsen.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s